Basilea Pharmaceutica

[4] Basilea was spun off from F. Hoffmann-La Roche in 2000 and has been listed as an independent company on the Swiss stock exchange since March 2004.

[23] Basilea was previously active in oncological research, but withdrew from it at the beginning of 2022 and has since been focusing purely on anti-infectives.

Isavuconazole's total global sales in the twelve-month period between October 2022 and September 2023 amounted to CHF 406 million.

[27] In the financial year 2023, Basilea Pharmaceutica AG, Allschwil generated company sales of CHF 157.6 million and employed 147 people.

[31] The company's research and development activities are focused on drugs for the treatment of severe, resistant bacterial infections and life-threatening, invasive fungal diseases.

It has an active effect against the bacterium Staphylococcus aureus (MRSA), including methicillin-resistant strains, and against penicillin-resistant Streptococcus pneumoniae (PRSP) bacteria, as well as against gram-negative pathogens such as Enterobacteriaceae.

[40] Basilea's distribution partner in the MENA region is Hikma Pharmaceuticals LLC;[41] Knight Therapeutics Inc. commercialises the antifungal Cresemba in South America.